Immorna Biotherapeutics Secures Over RMB 100 Million in Series A Financing to Advance mRNA-Based Vaccines and Therapeutics

Recently, Immorna (Hangzhou) Biotechnology Co., Ltd. (“Immorna”), an innovative mRNA therapeutics company, announced the completion of its Series A financing round, raising over RMB 100 million. The round was led by China Growth Capital, with participation from Zheshang Venture Capital, while CoWin Ventures, the lead investor in the angel round, continued to increase its investment. The proceeds will be used to advance the clinical trials of multiple infectious disease vaccine candidates and oncology therapeutic products both domestically and internationally.

Immorna was founded in 2019 and is a leading company in China’s mRNA industry, particularly distinguished by its extensive industrial experience in Chemistry, Manufacturing, and Controls (CMC). The company is dedicated to developing innovative drugs based on its mRNA platform. In addition to mRNA technology, Immorna is also developing novel immune adjuvants for application in recombinant subunit vaccines. The core founding team possesses decades of combined experience in vaccine and drug development both domestically and internationally. Dr. Wang Zihao, Chairman and CEO, has accumulated nearly ten years of expertise in mRNA technology R&D, with profound understanding and technical reserves in mRNA design and synthesis, delivery systems, and formulation. The company’s core platform technology based on self-amplifying mRNA (saRNA) is at an internationally advanced level, with applications spanning tumor immunotherapy, infectious disease vaccines, rare disease treatments, and medical aesthetics, offering unique advantages particularly in tumor immunotherapy. Currently, product development across several application areas is progressing smoothly, with some candidates having entered the stage of clinical trial application.

Dr. Wang Zihao, Chairman and CEO of Immornastated: “Since its inception, the Company has received strong support from multiple investment institutions, to which we extend our sincere gratitude. With the recent addition of several key members, our R&D team is now fully assembled. We are confident that all development pipelines will be accelerated, enabling the self-amplifying mRNA technology to achieve clinical application at an early date.”

Xiong Weiming, Partner at China Growth Capital, the lead investor in this round“We have maintained long-term attention and tracking of the innovative mRNA technology sector, and we are confident that truly leading enterprises will emerge in China. After thorough due diligence, we believe Immorna (Hangzhou) Biotechnology Co., Ltd. (Immorna) will be among them. Immorna has established its self-amplifying mRNA technology platform, with a rich pipeline encompassing infectious disease vaccines and oncology therapeutics. The company boasts advantages such as technological leadership, efficient execution, and extensive industrialization experience. We are pleased to lead Immorna’s Series A financing round and will provide all necessary assistance and support for its development.”

Huang Xin, Managing Partner at CoWin Ventures“The successive launches of mRNA COVID-19 vaccine products overseas have fully validated the application of mRNA technology in infectious disease vaccines. Due to its low-dose requirements and potent immunogenicity, self-amplifying mRNA holds broad prospects for applications in infectious disease prevention and cancer immunotherapy. We remain firmly optimistic about the future development of Immorna (Hangzhou) Biotechnology Co., Ltd. and will continue to provide our unwavering support.”

You Xiangdong, Partner at Zheshang Venture Capitalstated: “We are delighted to co-invest in this round of financing for Immorna. We believe that mRNA technology, as an emerging biopharmaceutical technology, offers diverse application avenues and significant growth potential. We are confident that the team at Immorna will leverage its robust technical capabilities to develop more and better mRNA vaccines and therapeutics, and we hope to connect additional resources to support Immorna’s development.”